SummaryAvalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.
As private payers rapidly shift from volume to value-based payments, they seek contracts that reward outcomes to improve patient clinical care. Our agreement will support this transformation for Boehringer Ingelheim’s diabetes alliance with Eli Lilly.
This agreement utilizes Inovalon and Avalere’s combined breadth of healthcare capabilities to generate new insights about real-world diabetes care, identify opportunities for improved outcomes, and deploy platforms for provider- and patient-level interventions.
By leveraging innovative technologies currently in use with more than 100 existing health plan customers, the partnership will leverage a more holistic and integrated support to outcomes-based contracting that will better align with payer needs and help improve quality and clinical/economic outcomes.